Editor's Note: Green and red arrows refer to intraday stock price movement.NEW YORK ( TheStreet) -- CHANGE IN RATINGS Archer Daniels Midland ( ADM) downgraded at BofA/Merrill from Buy to Underperform, Bank of America/Merrill Lynchs said. Favorable grains positions could reverse. $32 price target. American Eagle ( AEO) downgraded at Janney from Buy to Neutral, Janney Montgomery said. $15 price target. Channel checks continue to show weaker demand. Alkermes ( ALKS) upgraded at Leerink to Outperform, Leerink Swann said. ELN purchase should help augment organic growth potential. Sotheby's ( BID) downgraded at Craig-Hallum from Buy to Accumulate, Craig-Hallum said. Company is facing increased competition. $50 price target. Calpine ( CPN) upgraded at Dahlman Rose from Hold to Buy. $20 price target. Company has attractive exposure to California and Texas. Cisco Systems ( CSCO) rated new Buy at BGC Partners. $24 price target. Company has a solid balance sheet and is leveraged to growth in mobile video demand. Diodes ( DIOD) downgraded at BMO to Market Perform, BMO Capital Markets said. Valuation call, based on a $34 price target. FirstEnergy ( FE) price target raised at Citi to $41 from $36. Story improving but valuation reflects catalysts, Citigroup said. Maintain Hold rating. FirstEnergy ( FE) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Estimates also boosted, given better power market trends. Gamco Investors ( GBL) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $61 price target. Company is realizing higher organic growth. GenOn Energy ( GEN) downgraded at Dahlman Rose from Buy to Hold. Valuation call. Jones Apparel ( JNY) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $11 price target. Estimates also cut, as the company is facing lower end-market demand. Medivation ( MDVN) initiated at Citi with a Buy rating and $35 price target. Biopharma with two promising phase 3 trials, Citigroup said. Mindray Medical ( MR) upgraded at Oppenheimer from Perform to Outperform. $32 price target. Company is seeing better operating momentum, with China driving overseas growth. Ralcorp ( RAH) downgraded at William Blair from Outperform to Market Perform, William Blair said. Expect little upside potential from the CAG bid.